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Aims The impact of the quality of warfarin therapy on cardiovascular outcomes excluding stroke is largely unknown.
The aims of this study were to evaluate the association between the warfarin control and the incidence and out-
come of myocardial infarction (MI) and to validate the predictive value of the CHA2DS2-VASc score for MI in
atrial fibrillation (AF) patients taking warfarin.
...................................................................................................................................................................................................
Methods
and results
The nationwide FinWAF Registry consists of 54 568 AF patients (mean age 73.31 ± 10.7 years, 52% men) taking
warfarin. The quality of warfarin therapy was assessed continuously by calculating the time in therapeutic range
within a 60-day window using the Rosendaal method (TTR60). Adjusted Cox proportional hazards models were
prepared for the incidence of MI and cardiovascular mortality in six different TTR60 categories. During the
3.2 ± 1.6 years of follow-up, the annual incidence of MI (95% confidence interval) was 3.3% (3.0–3.5%), 2.9% (2.6–
3.3%), 2.4% (2.1–2.7%), 1.9% (1.7–2.2%), 1.7% (1.5–2.0%), and 1.2% (1.1–1.3%) among patients with TTR60 <40%,
40–50%, 50–60%, 60–70%, 70–80%, and >80%, respectively. Well-managed warfarin therapy (TTR60 > 80%) was
associated also with a lower cardiovascular mortality, whereas a high CHA2DS2-VASc score correlated with poor
outcome.
...................................................................................................................................................................................................
Conclusion Cardiovascular outcome was superior among AF patients with good warfarin control and in those with a low
CHA2DS2-VASc score. The inverse association between the TTR60 and incidence of MI and cardiovascular mortal-
ity indicate that in AF patients the quality of warfarin therapy is critical not only for prevention of stroke but also
with regard to cardiovascular outcome.
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Introduction
Atrial fibrillation (AF) is one of the major causes of stroke.1,2 In addi-
tion, AF is associated with increased risk of heart failure, myocardial
infarction (MI), cognitive impairment, and dementia.3–8 Management
of AF is focused on stroke prevention. According to the contempo-
rary management guidelines, lifelong oral anticoagulation (OAC)
therapy with a direct oral anticoagulant (DOAC) or a vitamin K
antagonist (VKA) should be considered for all AF patients apart from
those at very low stroke risk based on the CHA2DS2-VASc score.
9
Despite the outmost role of stroke prevention in management of
AF, other cardiovascular outcomes should not be overlooked.
Many cardiovascular diseases increase the risk of AF, and vice versa;
patients with AF frequently develop cardiovascular disorders
including MI.2,6,10
OAC therapy prevents more than two-thirds of ischaemic strokes
in patients with AF.11,12 On the other hand, the impact of the quality
of VKA therapy on the incidence and outcome of other cardiovascu-
lar events such as MI has not been examined in detail. When using a
VKA for stroke prevention, maintenance of the international normal-
ized ratio (INR) at therapeutic level (INR 2.0–3.0) is essential. In clini-
cal practice, the standard method to estimate the quality of long-
term VKA remedy is to calculate the percentage of time that the INR
values are in the therapeutic range (TTR).9,13 The results of recent
studies indicate that the higher the TTR, the better the outcome with
regard to the incidence of stroke and total mortality.14–17
In the nationwide FinWAF Registry, clinical information of a large
cohort of AF patients are linked to comprehensive laboratory data
including INR values. The aims of the current analysis were to evalu-
ate whether the quality of warfarin therapy was associated with inci-
dence and outcome of MI and to validate the predictive value of the
CHA2DS2-VASc score for MI in AF patients anticoagulated with
warfarin.
Methods
Data sources
The FinWAF is a retrospective cohort study based on data obtained
from seven nationwide health registries and six regional laboratory data-
bases. In Finland, every permanent resident, regardless of citizenship, has
personal identity code, which is used in all contacts with healthcare
authorities, hospitals, outpatient clinics, and pharmacies. Hence, the code
enables to link official data from healthcare registers and to investigate
potential associations between the cause of death, hospital discharge
diagnosis [10th revision of the International Statistical Classification of
Diseases (ICD-10) code], medication, and laboratory values.
Ethical aspects
The study was performed in accordance with Declaration of Helsinki and
the European Network of Centers for Pharmacoepidemiology and
Pharmacovigilance (ENCePP) Code of Conduct and registered to the
ENCePP e-register (EU PAS Register Number EUPAS4700). The study
protocol was approved by the local ethics committee. The permits to
collect and link data from the registries and laboratory databases were
received from the Social Insurance Institute, the National Institute
for Health and Welfare, the Population Register Center, and the
Statistics Finland.
Study population and follow-up
The inclusion criteria were (i) AF diagnosis, (ii) at least one warfarin pur-
chase, and (iii) at least one INR measurement. The whole Finnish popula-
tion was screened (Figure 1). A total of 55 072 patients fulfilled all the
inclusion criteria. After implementing the exclusion criteria (age < 18 -
years at the cohort entry date, residence outside Finland during the study
period, and no valid INR measurements during the follow-up), 54 568
patients remained eligible for the analysis. Of them 23 396 were new and
31 172 were previous warfarin users, respectively.
Cohort entry date (CED) was defined as the date of the first warfarin
purchase after 1 January 2007. Data from 1 January 2005 to the CED
were used to capture the baseline population characteristics. A patient
was categorized into the previous or new warfarin user group if the initial
warfarin purchase was made between 1 January 2005 and 31 December
2006 or after 1 January 2007, respectively. The follow-up began at CED
and continued until the patient died or to the end of the study period on
31 December 2011. This scheme ensured at least 2 years of potential
follow-up for every patient. When investigating the outcomes, the
follow-up ceased at the time of the first event.
International normalized ratio
measurements and time in the therapeutic
range
INR data were collected from the databases of six accredited regional
central laboratories. These laboratories analyse all blood samples taken
in their district, and they cover about two-thirds of the Finnish population
(3.5 million residents). Each of the laboratories complies with continuous
internal and external quality assurance schemes as recommended by the
Labquality (Helsinki, Finland).
The estimation of the quality of warfarin therapy was based on serial
INR measurements.16 Time-dependent TTR was calculated continuously
via linear interpolation using the Rosendaal method and reported as the
percentage of days that the INR values were between 2.0 and 3.0 within
the previous 60 days (TTR60). When evaluating the association between
the accomplishment of warfarin therapy and the incidence and outcome
of MI and cardiovascular mortality, the patients were divided into six
groups according to the TTR60 values: <40%, 40–50%, 50–60%, 60–70%,
70–80%, and >80%. TTR60 value 60–70% was used as a reference value.
A summary therapeutic range value (sTTR) covering the entire study
period was calculated for each patient to sum up the overall quality of
warfarin therapy.
Background variables
Information on age, gender, co-morbidities, and medications was collected
from seven nationwide healthcare registries (Supplementary material
online, Table S1). The ICD-10 codes used for identification of the co-mor-
bidities have been reported previously.16 CHA2DS2-VASc risk score was
used to summarize the background variables. It consists of Congestive heart
failure (1 point), Hypertension (1 point), Age >_75 (2 points), Diabetes melli-
tus (1 point), Stroke, TIA or systemic thromboembolisation (2 points),
Vascular disease (e.g. peripheral artery disease, prior MI), Age 65–74
(1 point) and Sex category (female sex, 1 point).9,18
Endpoints
The endpoints were categorized according to the ICD-10. The primary
endpoints included (i) first hospitalization due to MI (ICD-10 codes I21–
I22), (ii) MI mortality (ICD10 codes I21–I22), and (iii) cardiovascular mor-
tality (ICD-10 codes I00–I83, I99, Q20–Q28). In addition, we evaluated
whether the CHA2DS2-VASc score was associated with the risk and out-
come of MI. The diagnosis of MI was defined according to the
212 M.J.P. Raatikainen et al.
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international criteria, which was valid at the time of the data input into
the national registry.19
Statistical analyses
Baseline characteristics are reported as the mean ± standard deviation
for continuous variables and percentages for categorical variables. Data
management and all statistical analysis were performed using the R
language.20
Stratified incidence rates were estimated in each time-dependent TTR
category, and the 95% confidence intervals (CIs) were captured accord-
ing to the Poisson assumption. Hazard ratios (HRs) for different time-
dependent TTR levels compared with the reference group (TTR = 60–
70%) were estimated using the Cox proportional hazards model adjusted
for age, gender, and time-varying co-morbidities, including history of MI,
congestive heart failure, hypertension, diabetes, previous stroke, previous
transient ischaemic attack (TIA), renal impairment (serum creatini-
ne > 90mmol/l in women and > 100mmol/l in men), vascular disease, and
any previous hospitalization. The effects of adjusting covariates on the
outcomes are provided in Supplementary material online, Table S2. HRs
were accompanied by expected cumulative hazards, derived for an aver-
age study patient assumed to have a time-fixed TTR, and used to evaluate
the predicted cumulative incidences as recommended by Therneau and
Grambsch.21
To test for sensitivity, the results were rederived using the Cox
proportional hazards model with 30-, 90-, 180-, and 360-day time frames
for calculating the time-dependent TTR and by excluding patients who
did not have at least two separate warfarin purchases within 120 days
from the CED. Sensitivity analyses were also performed for previous
and new warfarin users, and on cohorts that excluded patients who
had an AF diagnosis only after the first purchase of warfarin, and
patients who had a diagnosis of any valve disorder accompanied with
their diagnosis of AF.
Results
Baseline characteristics and follow-up
The mean age of the study population was 73 ± 11 years (range 18–
101 years), and 52% of them were men. The most common underly-
ing diseases in the whole study population included hypertension
(24.2%), vascular diseases (25.2%), congestive heart failure (18.1%),
and diabetes (9.8%). A total of 12.3% and 4.4% of the patients had a
history of stroke/TIA and MI, respectively. Detailed information on
the baseline demographics among patients with the different TTR lev-
els are presented in Table 1.
The mean follow-up time was 3.2 ± 1.6 years (interquartile range
2.0–4.7 years), and the total number of treatment years was 128 941.
The median number of INR measurements was 1.36 per month
(interquartile range 0.78–1.95). The monthly rate of INR measure-
ments was lower among the previous warfarin users compared with
the new ones (1.43 ± 1.13 vs. 1.65± 1.26, P< 0.001). During the
follow-up period, 2502 MIs, 1214 deaths due to MI, and 6999 cardio-
vascular deaths were recorded. Hence, the annual incidence of MI,
death due to MI, and cardiovascular mortality among the study popu-
lation was 1.9% (95% CI 1.9–2.0), 0.9% (95% CI 0.9–1.0), and 5.3%
(95% CI 5.2–5.4), respectively.
Time-dependent therapeutic range as a
predictor of cardiovascular outcomes
The rate of MI was inversely related to the quality of warfarin therapy
(Table 2). The HR for MI was more than 1.5 times higher among
patients with TTR < 40% than in the reference population. In patients
with TTR60 >80%, the risk of MI (HR 0.7, 95% CI 0.6–0.8) and MI
Figure 1 Schematic presentation showing the selection of the study population. Whole Finnish population was screened and those fulfilling all
three inclusion criteria (warfarin purchase and INR measurement between 1 January 2007 and 31 December 2009 and AF diagnosis between
1 January 2005 and 31 December 2009) were eligible for the study. After exclusion (see Methods), a total of 54 568 patients were included in the
study.
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mortality and cardiovascular mortality (HR 0.8, 95% CI 0.7–0.9) were
significantly lower than in any other group.
The predicted cumulative incidence of MI is depicted in Figure 2,
and cumulative incidence of MI mortality and cardiovascular mortality
are shown in Figure 3. It was estimated that an average patient with
TTR60 < 40% would have had 9.9% risk of having MI during a 5-year
follow-up period. The corresponding numbers for MI mortality and
cardiovascular mortality would have been 5.6% and 37.8%, respec-
tively. In comparison, among patients with a TTR60 exceeding 80%
the risk of MI, MI mortality and cardiovascular mortality would have
been and 5.2%, 2.1% and 10.1%, respectively.
Sensitivity analyses testing different time frames (30, 90, 180, and
360 days) showed that a better TTR with any predefined time frame
was associated with an improved patient outcome for all reported
endpoint measures. The results also remained unchanged according
to the sensitivity analysis under the following conditions: the exclu-
sion of patients without at least two warfarin purchases within
120 days from CED, the exclusion of patients with an AF diagnosis
..........................................................................................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of the total study population and patients with various summary TTR levels in
patients with at least three international normalized ratio measurements
Variables Summary TTR level
<40%
(n5 8364)
40–50%
(n5 4261)
50–60%
(n56502)
60–70%
(n5 9729)
70–80%
(n511 547)
>80%
(n511 224)
Total
(n5 51 627)
Age (years)
Mean (SD) 71.7 (12.3) 72.9 (11.7) 73.9 (11.0) 74.4 (10.6) 74.1 (9.8) 72.6 (9.7) 73.3 (10.7)
Median (range) 74 (18–101) 75 (25–98) 76 (25–100) 76 (18–101) 75 (22–99) 73 (18–98) 75 (18–101)
<65,a,b n (%) 2291 (27.45) 1065 (25.0) 1365 (21.0) 1759 (18.1) 1940 (16.8) 2255 (20.1) 10 675 (20.7)
65–74,a,b n (%) 2110 (25.2) 1000 (23.5) 1598 (24.6) 2532 (26.0) 3487 (30.2) 3803 (33.9) 14 530 (28.1)
>_75 years,a,b n (%) 3963 (47.4) 2196 (51.5) 3539 (54.4) 5438 (55.9) 6120 (53.0) 5166 (46.0) 26 422 (51.2)
Gender, n (%)
Malea,b 4978 (59.5) 2316 (54.4) 3297 (50.7) 4731 (48.6) 5632 (48.8) 5997 (53.4) 26 951 (52.2)
Femalea,b 3386 (40.5) 1945 (45.7) 3205 (49.3) 4998 (51.4) 5915 (51.2) 5227 (46.6) 24 676 (47.8)
Co-morbidities, n (%)
CHFa,b 1859 (22.2) 948 (22.3) 1462 (22.5) 1906 (19.6) 1790 (15.5) 1367 (12.2) 9332 (18.1)
Cardiomyopathya,b 266 (3.2) 153 (3.6) 227 (3.5) 253 (2.6) 289 (2.5) 237 (2.1) 1425 (2.8)
Hypertensionb 2104 (25.2) 1063 (25.0) 1606 (24.7) 2380 (24.5) 2739 (23.7) 2607 (23.2) 12 499 (24.2)
Diabetesa,b 1043 (12.5) 479 (11.2) 791 (12.2) 1035 (10.6) 937 (8.1) 760 (6.8) 5045 (9.8)
Stroke or TIAa 937 (11.2) 472 (11.1) 834 (12.8) 1264 (13.0) 1460 (12.6) 1365 (12.2) 6332 (12.3)
Vascular diseasea,b 2455 (29.4) 1239 (29.1) 1751 (26.9) 2553 (26.2) 2714 (23.5) 2273 (20.3) 12985 (25.2)
Prior MIa,b 505 (6.0) 212 (5.0) 301 (4.6) 406 (4.2) 431 (3.7) 405 (3.6) 2260 (4.4)
Renal impairmenta,b 2021 (24.1) 1126 (26.4) 1605 (24.7) 2126 (21.9) 2097 (18.2) 1611 (14.4) 10 586 (20.5)
Pulmonary embolisma,b 169 (2.0) 76 (1.8) 92 (1.4) 164 (1.7) 173 (1.5) 108 (1.0) 782 (1.5)
DVTa,b 334 (4.00) 180 (4.2) 245 (3.8) 296 (3.0) 293 (2.5) 220 (2.0) 1568 (3.0)
Cancera,b 1710 (20.4) 872 (20.5) 1335 (20.5) 1977 (20.3) 2131 (18.5) 1939 (17.3) 9964 (19.3)
CHA2DS2VASc score
Mean (SD) 2. 7 (1.8) 2.8 (1.8) 3.0 (1.8) 3.0 (1.7) 2.8 (1.6) 2.6 (1.6) 2.8 (1.7)
Median (range) 3 (1–4) 3 (1–4) 3 (2–4) 3 (2–4) 3 (2–4) 2 (1–4) 3 (2–4)
0,a,b n (%) 1069 (12.8) 483 (11.3) 597 (9.2) 704 (7.2) 803 (7.0) 954 (8.5) 4610 (8.9)
1,a,b n (%) 1265 (15.1) 585 (13.7) 796 (12.2) 1239 (12.7) 1629 (14.1) 2006 (17.9) 7520 (14.6)
>_2,a,b n (%) 6030 (72.1) 3193 (74.9) 5109 (78.6) 7786 (80.0) 9115 (78.9) 8264 (73.4) 39 497 (76.5)
Medication, n (%)
Previous warfarin usera,b 4137 (49.5) 2377 (55.8) 4016 (61.8) 5972 (61.4) 6937 (60.1) 6474 (57.7) 29 913 (57.9)
New warfarin usera,b 4227 (50.5) 1884 (44.2) 2486 (38.2) 3757 (38.6) 4610 (39.9) 4750 (42.3) 21 714 (42.1)
Clopidogrela,b 454 (5.4) 190 (4.5) 273 (4.2) 415 (4.3) 412 (3.6) 354(3.2) 2098 (4.1)
Dipyridamole 238 (2.9) 104 (2.4) 176 (2.7) 273 (2.8) 309 (2.7) 253 (2.3) 1353 (2.6)
Beta-blockersa,b 6302 (75.4) 3283 (77.1) 5131 (78.9) 7749 (79.7) 9102 (78.8) 8687 (77.4) 40 254 (78.0)
Diltiazem/verapamil 399 (4.7) 227 (5.3) 396 (6.1) 550 (5.7) 700 (6.1) 651 (5.8) 2923 (5.7)
Class I or III AADsa,b 558 (6.7) 276 (6.5) 476 (7.3) 712 (7.3) 962 (8.3) 1060 (9.4) 4044 (7.8)
AAD, antiarrhythmic drug; CHF, congestive heart failure; DVT, deep venous thrombosis; MI, myocardial infarction; TIA, transient ischaemic attack.
aP-value <0.001 for test that proportion is equal in each TTR group.
bP-value <0.001 for test that there is a linear trend (either decreasing or increasing) in the variable by the summary TTR category.
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after warfarin purchase, distinguishing previous from new warfarin
users, and the exclusion of patients who were diagnosed with any
valve disorders accompanied with a diagnosis of AF.
Association between the CHA2DS2-VASc
score and risk of myocardial infarction
The mean CHA2DS2-VASc score in the entire study population was
2.8± 1.7. In the different TTR60 categories, the mean CHA2DS2-
VASc score varied between 2.6 and 3.0, indicating clinically significant
differences between the groups were unlikely. There was a strong
association between the CHA2DS2-VASc score and the risk of MI
(Table 3). Among patients with no risk factors, the incidence of MI
(2.88 per 1000 patient-years, 95% CI 1.82–4.58) was lower than in
any other group (P< 0.001). In comparison, among patients with
CHA2DS2-VASc score >5, the incidence rate was 39–64 per 1000
patient-years. A high CHA2DS2-VASc score was also a strong predic-
tor of MI mortality and cardiovascular death (Table 3). In patients
with high CHA2DS2-VASsc score (>2 points) and low quality of war-
farin therapy (TTR60 <_ 40%), MI rate was almost 20 times higher (3.8
vs. 0.2 per 100 patient-years) than in those with no CHA2DS2-VASc
.................................................................................................
Table 2 Number of events, incidence rates, and haz-
ard ratios (HR) of myocardial infarction, myocardial
infarction mortality, and cardiovascular mortality
among patients in the different time-dependent TTR
categories
TTR60 (%) Number
of events
Rate per
100 patient-
years
(95% CI)
HR
(95% CI)
P-value
Myocardial infarction
<_40 859 3.3 (3.0–3.5) 1.6 (1.4–1.8) <0.001
40–50 265 2.9 (2.6–3.3) 1.5 (1.2–1.7) <0.001
50–60 248 2.4 (2.1–2.7) 1.2 (1.0–1.5) 0.033
60–70 218 1.9 (1.7–2.2) 1 (reference)
70–80 203 1.7 (1.5–2.0) 0.9 (0.8–1.1) 0.447
>80 709 1.2 (1.1–1.3) 0.7 (0.6–0.8) <0.001
Myocardial infarction mortality
<_40 486 1.8 (1.6–2.0) 1.8 (1.5–2.2) <0.001
40–50 144 1.5 (1.3–1.8) 1.6 (1.2–2.0) <0.001
50–60 105 1.0 (0.8–1.2) 1.0 (0.8–1.4) 0.783
60–70 107 0.9 (0.8–1.1) 1 (reference)
70–80 91 0.8 (0.6–0.9) 0.9 (0.7–1.1) 0.316
>80 281 0.5 (0.4–0.5) 0.6 (0.5–0.8) <0.001
Cardiovascular mortality
<_40 3162 11.7 (11.3 –12.1) 2.0 (1.8–2.2) <0.001
40–50 714 7.6 (7.1–8.2) 1.3 (1.2–1.5) <0.001
50–60 670 6.2 (5.8 –6.7) 1.1 (1.0–1.2) 0.084
60–70 647 5.5 (5.1–6.0) 1 (reference)
70–80 497 4.1 (3.8–4.5) 0.8 (0.7–0.9) <0.001
>80 1309 2.2 (2.0–2.3) 0.5 (0.4–0.5) <0.001
The hazard ratios were adjusted for age, gender, congestive heart failure, hyper-
tension, diabetes, stroke, transient ischaemic attack, vascular disease, previous
hospitalization, and renal impairment.
Figure 2 Cumulative incidence of myocardial infarction among
the patients in the different time-dependent TTR60 categories.
Figure 3 Cumulative incidence of myocardial infarction mortality
(A) and cardiovascular mortality (B) among patients in the different
time-dependent TTR60 categories.
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points and excellent warfarin control (TTR60 > 80%) (for details see
Supplementary material online, Table S3 ).
A total of 2410 (4.4%) patients had prior MI, and 13 708 (25.1%)
patients had been diagnosed with vascular disease. Beta-blocker ther-
apy had favourable effect on MI rate [1.7 (1.6–1.8) with a beta-
blocker vs. 1.8 (1.6–2.1) with no beta-blocker] and cardiovascular
mortality [3.2 (3.1–3.4) vs. 7.4 (6.9–8.0)]. On the other hand, the rate
of MI [1.6 (1.5–1.8) vs. 10.0 (7.5–13.5)] and cardiovascular mortality
[4.0 (3.8–4.2) vs. 9.5 (7.2–12.6)] were higher among those using clopi-
dogrel compared with those using no adenosine diphosphate (ADP)
receptor antagonists.
Overall quality of warfarin therapy
The mean sTTR level capturing the entire follow-up period was
62± 25% (median 67%). sTTR was above 80% in 22% of the patients,
whereas in 16% of the patients, it was below 40%. In patients with
incident MI, the mean sTTR was lower than in patients without MI
(56.5± 23.1% vs. 62.0± 23.7%, P< 0.001). Similarly, both the MI mor-
tality (56.5± 24.3% vs. 61.9± 23.7%, P< 0.001) and the cardiovascular
mortality (56.2± 22.5% vs. 62.6± 23.8%, P< 0.001) were associated
with a lower sTTR.
Baseline characteristics associated with a low sTTR (<_40%)
included age <65 years, history of congestive heart failure, vascular
disease, diabetes, renal impairment, venous and pulmonary thrombo-
embolism, cancer, and CHA2DS2-VASc Score 0. A good sTTR
(>80%) was related to age 65–75 years and CHA2DS2-VASc Score 1.
Discussion
This is the first large-scale study showing that there is a strong associ-
ation between the quality of warfarin therapy and incidence and out-
come of MI in patients with AF. The risk of MI, death due to MI, and
....................................................................................................................................................................................................................
Table 3 Number of events and event rates (per 1000 person-years) stratified by the CHA2DS2-VASc risk score
CHA2DS2-VASc score Number of patients Number of events Time at risk (years) Event rate (95% CI)
Myocardial infarction
0 4780 18 6244 2.9 (1.8–4.6)
1 9495 90 13 790 6.5 (5.3–8.0)
2 15 301 240 23 087 10.4 (9.2–11.8)
3 19 852 433 29 055 14.9 (13.6–16.4)
4 17 694 560 24 394 23.0 (21.1–24.9)
5 13 087 529 17 241 30.7 (28.2–33.4)
6 7771 380 9544 39.8 (36.0–44.0)
7 3506 162 4136 39.2 (33.6–45.7)
8 1165 74 1199 61.7 (49.1–77.5)
9 234 16 251 63.9 (39.1–104.2)
Myocardial infarction mortality
0 4780 3 6244 0.5 (0.2–1.5)
1 9507 9 13 824 0.7 (0.3–1.3)
2 15 368 47 23 222 2.0 (1.5–2.7)
3 20 026 149 29 366 5.1 (4.3–6.0)
4 18 056 270 24 873 10.9 (9.6–12.2)
5 13 533 281 17 908 15.7 (14.0–17.6)
6 8136 259 10 067 25.7 (22.8–29.1)
7 3750 126 4411 28.6 (24.0–34.0)
8 1268 60 1322 45.4 (35.3–58.5)
9 263 10 283 35.4 (19.0–65.7)
Cardiovascular mortality
0 4780 43 6244 6.9 (5.1–9.3)
1 9507 116 13 824 8.4 (7.0–10.1)
2 15 368 307 23 222 13.2 (11.8–14.8)
3 20 026 736 29 366 25.1 (23.3–26.9)
4 18 056 1440 24 873 57.9 (55.0–61.0)
5 13 533 1648 17 908 92.0 (87.7–96.6)
6 8136 1419 10 067 141.0 (133.8–148.5)
7 3750 820 4411 185.9 (173.6–199.1)
8 1268 384 1322 290.6 (262.9–321.1)
9 263 86 283 304.0 (246.1–375.6)
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cardiovascular mortality were significantly lower among patients with
TTR60 over 80% than in the other TTR60 groups. Hence, the quality
of VKA therapy relates not only to the risk of stroke but also to the
risk and outcome of MI and overall cardiovascular mortality.
Moreover, our data corroborated that a high CHA2DS2-VASc score
is a powerful predictor of MI and cardiovascular outcome in AF
patients anticoagulated with warfarin.
Association between time-dependent
therapeutic range and incidence of myo-
cardial infarction
The quality of warfarin therapy is inversely correlated with the risk of
stroke in patients with AF.16,22 On the other hand, data on the rela-
tionship between TTR and the incidence of MI in patients with AF are
scant. Here, the risk of MI was lower among patients with TTR60
over 80% compared with the other TTR60 groups. It was estimated
that an average patient with poor INR control (TTR60 < 40%) would
have had almost 10% absolute risk of developing MI within the next
5 years. In contrast, in those with TTR above 80% the risk of MI
would have been almost twice lower (i.e. 5.2%).
These findings concur with those from previously published
smaller series. In the VKA arm of the SPORTIF III and IV trials, the
rate of MI was significantly higher in patients with TTR < 60% than in
those with TTR > 75%.23 In the RE-LY trial, the patients with
TTR >_65% had lower MI rate compared with those with TTR
<65%.24 More recently, Pastori et al.25 showed in a small prospective
cohort that the rate of combined endpoint of major adverse cardio-
vascular events including fatal or nonfatal MI and cardiovascular mor-
tality increased significantly across tertiles of TTR. None of these
studies were powered to provide detailed information on the rela-
tionship between TTR levels and the incidence and outcome of MI. In
contrast, the nationwide FinWAF cohort covered 3.5 million resi-
dents, i.e. 64% of the Finnish population. The large number of eligible
patients (almost 55 000) allowed us to assess the associations
between the incidence and outcome of MI and the quality of the war-
farin treatment at six different TTR categories (10% steps from <40%
to >80%). Another important advantage besides the size of the study
population was that we reported continuous TTR calculations using
a moving 60-day window, whereas in prior studies, TTR was
expressed over the entire study period. It is evident that the detec-
tion of temporal associations between the quality of VKA remedy
and clinical outcomes is more precise if TTR is calculated over a rela-
tive short time period before the event.
Association between therapeutic range
and cardiovascular outcome
Atrial fibrillation is one of the major causes of stroke and systemic
embolization.1,9 In addition, AF has been associated with cardiovascu-
lar hospitalization and adverse outcome in many cardiovascular dis-
orders.3–8 In patients with acute coronary syndrome, concomitant
AF predicts adverse outcome.26,27 The results of the WARIS II trial
indicate that warfarin is more effective than aspirin in secondary pre-
vention after MI among patients without AF,28 but the impact of war-
farin therapy on the outcome of MI in patients with AF is sparsely
characterized. In our study, the rate of MI mortality and cardiovascu-
lar mortality correlated inversely with the quality of warfarin therapy.
That is, in AF patients with TTR60 over 80%, the outcomes were
superior to any other TTR group. The estimated risk of dying for MI
within the next 5 years was 5.6% in a patient with poor INR control
(TTR60 < 40%) compared with 2.1% in a patient with good INR con-
trol (TTR > 80%). The corresponding number for cardiovascular
mortality was 37.8% vs. 10.1%, respectively. These novel findings of
this large-scale nationwide study are supported by the results of the
above-mentioned smaller studies23–25 and a recent meta-analysis.22
CHA2DS2-VASc score as a predictor of
myocardial infarction
The introduction of the CHA2DS2-VASc score has simplified stratifi-
cation of stroke risk.9,18 In general, patients without any clinical risk
factors for stroke do not need OAC therapy, while patients with
stroke risk factors (i.e. CHA2DS2-VASc score of 1 or more for men
and 2 or more for women) will benefit from OAC.9 In line with prior
data,29 our findings indicate that the CHA2DS2-VASc score is a
powerful predictor for MI and cardiovascular mortality in patients
with AF receiving warfarin. The risk was highest among those with
high CHA2DS2-VASsc score and poor warfarin control. Considering
that CHA2DS2-VASc score components are also related to the risk
of MI and cardiovascular death, this finding was rather anticipated.
Overall quality of warfarin therapy
In clinical practice, the standard method to estimate the quality of
long-term VKA therapy is to calculate the TTR.13 According to the
contemporary AF management guidelines, TTR should be as good as
possible.9 Maintaining the INR within the target range is difficult and
necessitates frequent monitoring of the INR and adjustment of the
VKA dose. Here, the median summary TTR for the entire study
period was 67%. Although it was in the same range or better than the
TTR in recent randomized trials comparing warfarin and DOACs,12
it was still far below the proposed minimum target level of more than
80%. In accordance with the results of previous studies,30 young age,
cardiovascular co-morbidities, and cancer were associated with a
poor TTR.
Effect of concomitant medication
Beta-blocker use was associated with a lower MI rate and a better
cardiovascular outcome as expected. Estimation of the net effect of
ADP receptor antagonists is more difficult in a cohort of unselected
AF patients. Higher risk of MI and worse cardiovascular outcome in
patients using ADP receptor antagonists was most likely due to the
preferable use of these agents in high-risk patients with recent ischae-
mic events or coronary interventions and not a true negative effect.
The differences in the use of concomitant drugs in the various TTR60
categories were so small that any clinically significant effect is unlikely.
Limitations
All the nationwide registries used in our study have been validated
and the diagnoses have proved to be accurate.31 Nevertheless, a
major limitation of our study was that no information on some cardi-
ovascular risk factors such as smoking, alcohol consumption, and
dietary habits were available. Moreover, data on some concomitant
drugs that may have influenced the outcome were not accessible
either because they were available over the counter (e.g. aspirin) or
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not included in data collection permission (angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers).
The exact reasons behind poor TTR remain to be established.
Although the overall findings remained unchanged in the sensitivity
analysis investigating the effects of previous hospitalizations, it is pos-
sible that in some cases TTR was low, because warfarin was discon-
tinued on purpose (e.g. due to surgical interventions, cancer,
bleeding). The impact of a particular factor or a risk score such as the
CHA2DS2-VASc is best tested in non-anticoagulated patients with a
broad range of risk factors. In our study, all patients were already
using warfarin, which may have had some influence on the results.
Finally, our study did not provide any information on the effect of
DOACs on the risk and outcome of MI, because during the study
period, no long-term data on clinical use of DOACs were available.
Clinical implications
According to the contemporary guidelines,9,32 VKA monotherapy is
sufficient in AF patients with stable coronary artery disease and con-
comitant antiplatelet therapy should be avoided in the absence of
acute coronary syndrome or recent coronary stent implantation. Our
findings underscore the importance of high-quality INR control.
Calculating the TTR over a long-time period is not clinically practical,
and physicians should be encouraged to use continuously calculated
time-dependent TTR for follow-up of the quality of VKA therapy. Our
data indicate that a 60-day TTR window provides a proper means for
this purpose. A low continuously calculated TTR is not only a warning
sign of stroke but also a predictor of MI and poor cardiovascular out-
come in patients with AF. Given the sound relationship between the
warfarin control and risk and outcome of MI, we recommend that the
minimum TTR target in AF patients taking warfarin should be at least
80%. If good INR control is not possible, one should consider switch-
ing to DOAC therapy. Finally, the finding that a high CHA2DS2-VASc
score is associated with elevated risk of MI indicates that management
of other risk factors such as hypertension and dyslipidaemia is particu-
larly important in anticoagulated AF patients.
Conclusions
In patients with AF, well-managed warfarin therapy is associated not
only with a low risk of stroke but also that of MI and cardiovascular
mortality. The inverse association between continuously evaluated
TTR and the risk of MI and cardiovascular outcomes further support
to our earlier conclusion that the TTR in AF patients using warfarin
should be targeted at least at 80%. A high CHA2DS2-VASc score par-
allels with an elevated risk of MI among patients with AF.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
Acknowledgements
We thank Bristol-Myers Squibb, Finland, for the practical support
during the study. Pia Annunen, Houssem Khanfir, and Fabian Hoti are
acknowledged for their contribution to the study design. We also
thank the regional laboratories: HUSLAB, Helsinki; TYKSLAB, Turku;
FIMLAB, Tampere and FIMLAB, Central Finland; ISLAB, Kuopio; and
NORDLAB, Oulu.
Funding
Bristol-Myers Squibb, Finland and Pfizer, Finland; the Finnish Foundation
for Cardiovascular Research; Helsinki University Hospital District
research fund [Y2016SK007].
Conflict of interest: none declared.
References
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor
for stroke: the Framingham Study. Stroke 1991;22:983–988.
2. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-
Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS,
Benjamin EJ, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk
factors, and mortality in the Framingham Heart Study: a cohort study. Lancet
2015;386:154–162.
3. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB,
Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation
and congestive heart failure and their joint influence on mortality: the
Framingham Heart Study. Circulation 2003;107:2920–2925.
4. Ball J, Carrington MJ, Stewart S. Mild cognitive impairment in high-risk patients
with chronic atrial fibrillation: a forgotten component of clinical management?
Heart 2013;99:542–547.
5. Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, Pai M,
McManus DD, Schnabel RB, Magnani JW, Yin X, Levy D, Pencina MJ, Larson MG,
Ellinor PT, Benjamin EJ. Atrial fibrillation patterns and risks of subsequent stroke,
heart failure, or death in the community. J Am Heart Assoc 2013;2:e000126.
6. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker
EL, Judd S, Howard VJ, Howard G, Herrington DM, Cushman M. Atrial fibrillation
and the risk of myocardial infarction. JAMA Intern Med 2014;174:107–114.
7. Aldrugh S, Sardana M, Henninger N, Saczynski JS, McManus DD. Atrial fibrillation,
cognition and dementia: a review. J Cardiovasc Electrophysiol 2017;28:958–965.
8. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo
AA. Atrial fibrillation as risk factor for cardiovascular disease and death in
women compared with men: systematic review and meta-analysis of cohort stud-
ies. BMJ 2016;532:h7013.
9. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener
HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA,
Schotten U, Van PB, Vardas P, Agewall S, Camm J, Baron EG, Budts W, Carerj S,
Casselman F, Coca A, de CR, Deftereos S, Dobrev D, Ferro JM, Filippatos G,
Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A,
McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski
P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL,
Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation devel-
oped in collaboration with EACTS. Eur Heart J 2016;37:2893–2962.
10. Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial fibrillation and myocardial
infarction: a systematic review and appraisal of pathophysiologic mechanisms.
J Am Heart Assoc 2016;5:e003347.
11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to pre-
vent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
2007;146:857–867.
12. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD,
Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison
of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial
fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–962.
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Brie¨t E. A method to determine the
optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236–239.
14. Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer
DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP,
Peterson ED. Patients’ time in therapeutic range on warfarin among US patients
with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 2015;170:
141–148, 148.e1.
15. Senoo K, Lip GY. Female sex, time in therapeutic range, and clinical outcomes in
atrial fibrillation patients taking warfarin. Stroke 2016;47:1665–1668.
16. Lehto M, Niiranen J, Korhonen P, Mehtala J, Khanfir H, Hoti F, Lassila R,
Raatikainen P. Quality of warfarin therapy and risk of stroke, bleeding, and
218 M.J.P. Raatikainen et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/article-abstract/4/4/211/4921239 by N
ational Library of H
ealth Sciences user on 07 February 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..mortality among patients with atrial fibrillation: results from the nationwide
FinWAF Registry. Pharmacoepidemiol Drug Saf 2017;26:657–665.
17. Liu S, Li X, Shi Q, Hamilton M, Friend K, Zhao Y, Horblyuk R, Hede S, Shi L.
Outcomes associated with warfarin time in therapeutic range among US veterans
with nonvalvular atrial fibrillation. Curr Med Res Opin 2017;34:1–7.
18. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratifica-
tion for predicting stroke and thromboembolism in atrial fibrillation using a novel
risk factor-based approach: the euro heart survey on atrial fibrillation. Chest
2010;137:263–272.
19. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D,
Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S,
Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E,
Sharrett AR, Sorlie P, Tunstall-Pedoe H. Case definitions for acute coronary
heart disease in epidemiology and clinical research studies: a statement from the
AHA Council on Epidemiology and Prevention; AHA Statistics Committee;
World Heart Federation Council on Epidemiology and Prevention; the European
Society of Cardiology Working Group on Epidemiology and Prevention; Centers
for Disease Control and Prevention; and the National Heart, Lung, and Blood
Institute. Circulation 2003; 108:2543–2549.
20. R: Regulatory Compliance and Validation Issues: A Guidance Document for the
Use of R in Regulated Clinical Trial Environments. https://www r-project org/.
21. Therneau T, Grambsch P. Expected survival. In: T Therneau, P Grambsch, eds.
Modelling Survival Data: Extending the Cox Model. New York: Springer-Verlag;
2000. p261–287.
22. Carmo J, Ferreira J, Costa F, Carmo P, Cavaco D, Carvalho S, Morgado F,
Adragao P, Mendes M. Non-vitamin K antagonist oral anticoagulants compared
with warfarin at different levels of INR control in atrial fibrillation: a meta-
analysis of randomized trials. Int J Cardiol 2017;244:196–201.
23. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW.
Comparison of outcomes among patients randomized to warfarin therapy
according to anticoagulant control: results from SPORTIF III and V. Arch Intern
Med 2007;167:239–245.
24. Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment
with dabigatran: comprehensive analysis of individual subject data by treatment.
Vasc Health Risk Manag 2013;9:599–615.
25. Pastori D, Pignatelli P, Saliola M, Carnevale R, Vicario T, Del BM, Cangemi R,
Barilla F, Lip GY, Violi F. Inadequate anticoagulation by vitamin K antagonists is
associated with major adverse cardiovascular events in patients with atrial fibrilla-
tion. Int J Cardiol 2015;201:513–516.
26. Almendro-Delia M, Valle-Caballero MJ, Garcia-Rubira JC, Mu~noz-Calero B,
Garcia-Alcantara A, Reina-Toral A, Benı´tez-Parejo J, Hidalgo-Urbano R.
Prognostic impact of atrial fibrillation in acute coronary syndromes: results from
the ARIAM registry. Eur Heart J Acute Cardiovasc Care 2014;3:141–148.
27. Gorenek B, Kudaiberdieva G. Atrial fibrillation in acute ST-elevation myocardial
infarction: clinical and prognostic features. Curr Cardiol Rev 2012;8:281–289.
28. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or
both after myocardial infarction. N Engl J Med 2002;347:969–974.
29. Kim KH, Kim W, Hwang SH, Kang WY, Cho SC, Kim W, Jeong MH. The
CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial
infarction patients irrespective of presence of atrial fibrillation. J Cardiol 2015;65:
121–127.
30. Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip
GY. Time in therapeutic range and major adverse outcomes in atrial fibrillation
patients undergoing percutaneous coronary intervention: the Atrial Fibrillation
Undergoing Coronary Artery Stenting (AFCAS) registry. Am Heart J 2017;190:
86–93.
31. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review.
Scand J Public Health 2012;40:505–515.
32. Chou AY, Mancini GB. Warfarin monotherapy in atrial fibrillation patients with
stable coronary disease one year after myocardial infarction/stent: two birds
with one stone? Can J Cardiol 2015;31:1070–1072.
The quality of warfarin therapy and risk of myocardial infarction 219
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/article-abstract/4/4/211/4921239 by N
ational Library of H
ealth Sciences user on 07 February 2019
